What question did this study set out to answer?

To assess the effects of GLP-1 and GLP-1/GIP receptor agonist shortages on glycemic control.

May 7, 2026

Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study

Puntos clave

To assess the effects of GLP-1 and GLP-1/GIP receptor agonist shortages on glycemic control.
Single center study design
Assessment of patient HbA1c levels
Evaluation of therapy interruptions up to 12 months
Shortages significantly increased patients' HbA1c levels
Adverse clinical outcomes are likely due to prolonged shortages
Further studies needed to explore long-term effects of shortages on glycemic control

Resumen

= 1.00). Shortages of incretin therapy significantly increased patients' HbA1c levels up to 12 months post interruption. Long-term shortages or restrictions of these agents are likely to lead to adverse clinical outcomes. Further studies are needed to assess the outcomes of prolonged shortages or restrictions of these therapies.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Dacon et al. (Tue,) studied this question.

synapsesocial.com/papers/69fbe3aa164b5133a91a2f69 https://doi.org/https://doi.org/10.1177/08971900261449175

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo